CA Patent

CA2841969A1 — Fixed dose combination of bimatoprost and brimonidine

Assigned to Allergan Inc · Expires 2013-01-24 · 13y expired

What this patent protects

The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma.

USPTO Abstract

The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number
CA2841969A1
Jurisdiction
CA
Classification
—
Expires
2013-01-24
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.